NEXT-GENERATION CANCER SCREENING DEVICE INTRODUCED
HOUSTON, TX: February 4, 2009 — Houston-based Trimira™ LLC has introduced Identafi™ 3000, a small, cordless, handheld device that can detect oral cancer. The device uses a three-wavelength optical illumination and visualization system to allow dental professionals to catch early cancers not visible to the naked eye. This effective and affordable device will aid in early detection of oral cancer, which has reached epidemic levels, due in part to the lack of effective, broad-based early detection programs.
Identafi 3000 uses white, violet, and amber wavelengths of light to excite oral tissue in distinct and unique ways. Biochemical changes can be monitored with fluorescence, while morphological changes can be monitored with reflectance. This multiple wavelength technology identifies abnormal tissue with more accuracy than the single color approaches currently on the market. The ability to read metabolic and physiologic differences makes it easier to distinguish between normal and abnormal tissue. The combined system of fluorescence and reflectance uses the body's natural tissue properties as an adjunctive tool for oral mucosal examination.
Identafi 3000 is supported by a national team of trained sales representatives and is available through most major U.S. dental dealers. It can be seen at the Chicago Midwinter Meeting, in the Trimira booth, #865.
TRIMIRA™ LLC is a subsidiary of Remicalm LLC, a privately held medical diagnostic and imaging device company. Other subsidiaries are working on screening and diagnostic devices for skin, cervical, gastrointestinal, and bladder cancers. Remicalm's core technologies are based on high-speed, high-resolution capabilities from its patented optical processing technology platforms and include the ability to read metabolic and physiologic differences in diseased and healthy tissue in the human body. For more information, go to www.trimira.net.